Hasil Pencarian - Beth Overmoyer

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature

    Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature oleh Jennifer Y. Ge, Beth Overmoyer

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Copy Number Variation in Inflammatory Breast Cancer

    Copy Number Variation in Inflammatory Breast Cancer oleh Aditi Hazra, Andrea O’Hara, Kornelia Polyak, Faina Nakhlis, Beth T. Harrison, Antonio Giordano, Beth Overmoyer, Filipa Lynce

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Inflammatory breast cancer appearance at presentation is associated with overall survival

    Inflammatory breast cancer appearance at presentation is associated with overall survival oleh Wintana Balema, Diane Liu, Yu Shen, Randa El‐Zein, Bisrat G. Debeb, Megumi Kai, Beth Overmoyer, Kathy D. Miller, Huong T. Le‐Petross, Naoto T. Ueno, Wendy A. Woodward

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer

    Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer oleh Sonia Pernas, Jennifer L. Guerriero, Sergey Naumenko, Shom Goel, Meredith M. Regan, Jiani Hu, Beth T. Harrison, Filipa Lynce, Nancy U. Lin, Ann Partridge, Aki Morikawa, John Hutchinson, Elizabeth A. Mittendorf, Artem Sokolov, Beth Overmoyer

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer

    Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer oleh Sara M Tolaney, Tianyu Li, Edward T Richardson, Judith Agudo, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Adrienne G Waks, Tanya E Keenan, Nabihah Tayob, Gerburg M Wulf, Victoria Attaya, Leilani Anderson, Ian E Krop, Eliezer M Van Allen

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer

    Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer oleh Ana C. Garrido-Castro, Meredith M. Regan, Samuel M. Niman, Faina Nakhlis, Claire Remolano, Jennifer M. Rosenbluth, Caroline Block, Laura E. Warren, Jennifer R. Bellon, Eren Yeh, Beth T. Harrison, Elizabeth Troll, Nancy U. Lin, Sara M. Tolaney, Beth Overmoyer, Filipa Lynce

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

    Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study oleh Romualdo Barroso-Sousa, Tanya E. Keenan, Tianyu Li, Nabihah Tayob, Lorenzo Trippa, Ricardo G. Pastorello, Edward T. Richardson III, Deborah Dillon, Zohreh Amoozgar, Beth Overmoyer, Stuart J. Schnitt, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer Van Allen, Dan G. Duda, Sara M. Tolaney

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial

    Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial oleh Jorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E. Buendia-Buendia, Alyssa Pereslete, Daniel L. Abravanel, Arlindo R. Ferreira, Eileen Wrabel, Karla Helvie, Melissa E. Hughes, Ann H. Partridge, Beth Overmoyer, Nancy U. Lin, Nabihah Tayob, Sara M. Tolaney, Nikhil Wagle

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer

    TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer oleh Filipa Lynce, Laura E. Stevens, Zheqi Li, Jane E. Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M. Force, Tufia C. Haddad, Naoto Ueno, Vered Stearns, Antonio C. Wolff, Amy S. Clark, Jennifer R. Bellon, Edward T. Richardson, Justin M. Balko, Ian E. Krop, Eric P. Winer, Paulina Lange, E. Shelley Hwang, Tari A. King, Sara M. Tolaney, Alastair Thompson, Gaorav P. Gupta, Elizabeth A. Mittendorf, Meredith M. Regan, Beth Overmoyer, Kornelia Polyak

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis

    Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis oleh Priscilla K. Brastianos, Matthew R. Strickland, Eudocia Quant Lee, Nancy Wang, Justine V. Cohen, Ugonma Chukwueke, Deborah Anne Forst, April Eichler, Beth Overmoyer, Nancy U. Lin, Wendy Y. Chen, Aditya Bardia, Dejan Juric, Ibiayi Dagogo-Jack, Michael D. White, Jorg Dietrich, Naema Nayyar, Albert E. Kim, Christopher Alvarez-Breckenridge, Maura Mahar, Joana L. Mora, Brian V. Nahed, Pamela S. Jones, Helen A. Shih, Elizabeth R. Gerstner, Anita Giobbie-Hurder, Scott L. Carter, Kevin Oh, Daniel P. Cahill, Ryan J. Sullivan

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: